Skip to main content

Table 2 Univariate and multivariate analyses of OS with Cox regression models

From: Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab

Covariate Univariate analysis (n = 65) Multivariate analysis (n = 65)
HR 95% C.I. P-value HR 95% C.I. P-value
Group
 irAE Reference     Reference    
 non-irAE 6.081 2.373 15.582 < 0.001 9.543 3.336 27.302 < 0.001
ECOG PS
 0 Reference     Reference    
  ≥ 1 2.673 0.960 7.444 0.060 1.271 0.425 3.805 0.622
Number of metastatic sites
  < 2 Reference     Reference    
  ≥ 2 1.465 0.763 2.812 0.251 2.147 1.016 4.538 0.045
ALP
 Low Reference     Reference    
 High 2.259 1.284 3.97.3 0.005 2.499 1.272 4.913 0.008
Disease status
 Recurrence Reference     Reference    
 Stage IV 1.584 0.915 2.743 0.101 0.813 0.420 1.577 0.541
NLR
 Low (< 4) Reference     Reference    
 High (≥4) 1.716 0.991 2.971 0.054 1.551 0.810 2.971 0.185
  1. ALP alkaline phosphatase, ECOG PS Eastern Cooperative Oncology Group Performance Status, irAE immune-related adverse event
\